Compare EPSN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | SPRO |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | 25 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 156.3M |
| IPO Year | 2018 | 2017 |
| Metric | EPSN | SPRO |
|---|---|---|
| Price | $5.63 | $2.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 153.7K | ★ 861.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | $283.00 | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $4.20 | $1.80 |
| 52 Week High | $8.50 | $3.09 |
| Indicator | EPSN | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 54.76 |
| Support Level | $5.57 | $2.18 |
| Resistance Level | $5.91 | $3.07 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 5.22 | 57.50 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.